Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Article from the 9th.Mentions rgbp
https://www.mmjreporter.com/oncology-pharma-inc-otcmkts-onph-eyes-partnership-with-exclusive-rights-openings-41760
Our friends over at on ph have news on starting trials
I've posted what I thought was relevant from onph relating to rgbp and some have been removed. I think this is relevant.
https://www.otcmarkets.com/stock/ONPH/news/Oncology-Pharma-Inc-To-Move-to-Conducting-Trials-on-Licensed-IP?id=312297
Thank you
Is this relevant to us?
https://backend.otcmarkets.com/otcapi/company/financial-report/291431/content
Yeppers
I have about the same number of shares you do
No info on pg.en on otc market site. Found article below, sorry if it's already been posted
https://topnewsguide.com/2021/07/07/regen-biopharma-inc-otcmkts-rgbp-share-going-up-the-charts-again/
Between now and my bday Aug 11.
#2
Safe travels
"The Company's established portfolio of licensing agreements is expected to allow the company the ability to develop its own innovations to stand out amongst its peers."
News... Onph
Oncology Pharma, Inc. is Entering Into the Next Phase of its Growth and Expansion PhasePress Release | 06/30/2021
SAN FRANCISCO, CA / ACCESSWIRE / June 30, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. (the "Company") is developing a program to establish the use of its license utilizing NR2F6 agonists and antagonists coupled with the proprietary drug delivery systems in the treatment of various disorders including human pancreatic cancer and colon cancer. The work the Company is contracting to conduct is intended to do pre-clinical trials leading into seeking FDA approval for the combined efforts. Our team of industry experts and advisors have the expertise to lead the Company to efficiently conduct this next phase of development.
The developing program will allow Oncology Pharma to begin its own path towards producing proprietary intellectual property, for the pursuit and development of new therapies. The Company's established portfolio of licensing agreements is expected to allow the company the ability to develop its own innovations to stand out amongst its peers.
Also works with CELZ
News from Onph...
SAN FRANCOSCO, CA / ACCESSWIRE / June 15, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. (the 'Company') has been continuing its research and work reviewing and implementing collaboration between its interests in therapy, delivery and trial experience amongst its licensed products. The Company is in the early stages of reviewing the work and exploring opportunities between the synergistic value of its licensed Intellectual Properties and applying its expertise towards advancing the licensed IP we have with NanoSmart, Sybleu, Regen Biopharma and Ribera Solutions. The Company believes that it can take advantage internally of economies of scale and new IP can be created through a combination of therapies and delivery mechanisms.
In addition to seeking ways to enhance value with its existing portfolio of assets, Oncology Pharma has begun discussions within its network to identify key players to implement its goals. Being able to produce its own intellectual properties would be a key building block in the Company's objective towards expansion.
Oncology Pharma will further be looking into potentially utilizing a single CRO (Clinical Research Organization), in conjunction with its expertise within the Company, which management believes will save time and expense in getting the IP through the next steps of its development.
You enjoying this beautiful Midwestern morning?
SCHEDULE AN APPOINTMENT
?
PROFESSOR OF NEUROSCIENCES
Santosh Kesari, M.D., Ph.D.
Chair, Department of Translational Neurosciences
Director of Neuro-oncology
310-829-8265 SANTOSH.KESARI@PROVIDENCE.ORG
About Us Santosh Kesari, M.D., Ph.D.
Dr. Santosh Kesari is a board-certified neurologist and neuro-oncologist and is currently Chair and Professor, Department of Translational Neuro-oncology and Neurotherapeutics, Saint John’s Cancer Institute.
He is also Director of Neuro-oncology at Pacific Neuroscience Institute, Providence Saint John’s Health Center and Providence Little Company of Mary Medical Center Torrance, and leads the Pacific Neuroscience Research Center at Pacific Neuroscience Institute.
Dr. Kesari is ranked among the top 1% of neuro-oncologists and neurologists in the nation, according to Castle Connolly Medical Ltd and an internationally recognized scientist and clinician.
He is a winner of an Innovation Award by the San Diego Business Journal. He is on the advisory board of American Brain Tumor Association, San Diego Brain Tumor Foundation, Chris Elliott Fund, Nicolas Conor Institute, Voices Against Brain Cancer, and Philippine Brain Tumor Alliance. He has been the author of over 250 scientific publications, reviews, or books.
He is the inventor on several patents and patent applications, and founder and advisor to many cancer and neurosciences focused biotech startups. In addition, he is a member of the Los Angeles Biomedical Research Institute.
Dr. Kesari has had a long-standing interest in cancer stem cells and studies their role in the formation of brain tumors and resistance to treatment. He believes that in order to cure patients with brain tumors we first need to gain a better molecular and biological understanding of the disease. A physician/scientist, Kesari harnesses his experience in surgery, chemotherapy, immunotherapy, radiation therapy and novel devices to help develop Precision Therapeutic Strategies that will advance medicine to a new stage in the battle against brain tumors and eradicate the disease.
This guy.... Dr. Kesari is ranked among the top 1% of neuro-oncologists and neurologists in the nation, according to Castle Connolly Medical Ltd and an internationally recognized scientist and clinician.
I hope so.
You know we got something when a company locks up a 15 year deal. You ain't going to do something like that in the hopes of nothing coming out of it. That is what has made me a believer in this Co. That and the other patents, IP.
I'm thinking min $. 50, max$3.00(12 billion plus market cap)
Thanks Skiluc
Thanks for keeping it real!
I like your opinion, thank you!
Roameo, Roameo wherefore art thou Roameo?
Just got back from vacation not sure if this has been posted.
https://www.sec.gov/Archives/edgar/data/1589150/000160706221000145/rgbp053121form8k.htm
Back at ya brother!
yeah it is
The onph news along with the rgbp Sec of State filing is a nice combo!
https://www.filingre.com/stock/RGBP
Somebody subscribe to confirm, all my money is in this
Nice find
I appreciate it!
Finding true gems like this aren't for flipping. You stick with the smart choice. Patience pays off!
Just joking with them. I usually find news but don't read it just get it on the board so others can decipher if I can't.
Hope that's what you meant.
Thanks twice
I do the finding you do the reading between the lines, lol.
Thanks bud!
News out on Oncology...Not sure if it relates to us or not.
Oncology Pharma, Inc. Is Pursuing the Development of Its Small Molecule Drug for the Treatment of Colon Cancer
Yeah every morning, scrolling and looking for every bit of info, news.
Papa needs a new pair of shoes.
Thanks, just found was about to post.
Awfully nice company to be in a list with!
My thoughts as well.
Can't argue with you on that